OPINION OF THE COURT
GONZALES V. RAICH
545 U. S. ____ (2005)
SUPREME COURT OF THE UNITED STATES
NO. 03-1454
ALBERTO R. GONZALES, ATTORNEY GENERAL, et al.,
PETITIONERS
v. ANGEL McCLARY RAICH et al.
on writ of certiorari to the united states court of
appeals for the ninth circuit
[June 6, 2005]
Justice Stevens delivered the
opinion of the Court.
California is one of at least
nine States that authorize the use of marijuana for medicinal
purposes.[
Footnote 1] The
question presented in this case is whether the power vested in
Congress by Article I, §8, of the Constitution “[t]o make all Laws
which shall be necessary and proper for carrying into Execution”
its authority to “regulate Commerce with foreign Nations, and among
the several States” includes the power to prohibit the local
cultivation and use of marijuana in compliance with California
law.
I
California has been a pioneer in
the regulation of marijuana. In 1913, California was one of the
first States to prohibit the sale and possession of
marijuana,[
Footnote 2] and at
the end of the century, California became the first State to
authorize limited use of the drug for medicinal purposes. In 1996,
California voters passed Proposition 215, now codified as the
Compassionate Use Act of 1996.[
Footnote 3] The proposition was designed to ensure that
“seriously ill” residents of the State have access to marijuana for
medical purposes, and to encourage Federal and State Governments to
take steps towards ensuring the safe and affordable distribution of
the drug to patients in need.[
Footnote 4] The Act creates an exemption from criminal
prosecution for physicians,[
Footnote 5] as well as for patients and primary caregivers
who possess or cultivate marijuana for medicinal purposes with the
recommendation or approval of a physician.[
Footnote 6] A “primary caregiver” is a person who has
consistently assumed responsibility for the housing, health, or
safety of the patient.[
Footnote
7]
Respondents Angel Raich and Diane
Monson are California residents who suffer from a variety of
serious medical conditions and have sought to avail themselves of
medical marijuana pursuant to the terms of the Compassionate Use
Act. They are being treated by licensed, board-certified family
practitioners, who have concluded, after prescribing a host of
conventional medicines to treat respondents’ conditions and to
alleviate their associated symptoms, that marijuana is the only
drug available that provides effective treatment. Both women have
been using marijuana as a medication for several years pursuant to
their doctors’ recommendation, and both rely heavily on cannabis to
function on a daily basis. Indeed, Raich’s physician believes that
forgoing cannabis treatments would certainly cause Raich
excruciating pain and could very well prove fatal.
Respondent Monson cultivates her own
marijuana, and ingests the drug in a variety of ways including
smoking and using a vaporizer. Respondent Raich, by contrast, is
unable to cultivate her own, and thus relies on two caregivers,
litigating as “John Does,” to provide her with locally grown
marijuana at no charge. These caregivers also process the cannabis
into hashish or keif, and Raich herself processes some of the
marijuana into oils, balms, and foods for consumption.
On August 15, 2002, county deputy sheriffs and
agents from the federal Drug Enforcement Administration (DEA) came
to Monson’s home. After a thorough investigation, the county
officials concluded that her use of marijuana was entirely lawful
as a matter of California law. Nevertheless, after a 3-hour
standoff, the federal agents seized and destroyed all six of her
cannabis plants.
Respondents thereafter brought this action
against the Attorney General of the United States and the head of
the DEA seeking injunctive and declaratory relief prohibiting the
enforcement of the federal Controlled Substances Act (CSA), 84
Stat. 1242, 21 U. S. C. §801
et seq., to the extent
it prevents them from possessing, obtaining, or manufacturing
cannabis for their personal medical use. In their complaint and
supporting affidavits, Raich and Monson described the severity of
their afflictions, their repeatedly futile attempts to obtain
relief with conventional medications, and the opinions of their
doctors concerning their need to use marijuana. Respondents claimed
that enforcing the CSA against them would violate the Commerce
Clause, the Due Process Clause of the Fifth Amendment, the Ninth
and Tenth Amendments of the Constitution, and the doctrine of
medical necessity.
The District Court denied respondents’ motion
for a preliminary injunction.
Raich v.
Ashcroft,
248 F. Supp. 2d 918 (ND Cal. 2003). Although the court found
that the federal enforcement interests “wane[d]” when compared to
the harm that California residents would suffer if denied access to
medically necessary marijuana, it concluded that respondents could
not demonstrate a likelihood of success on the merits of their
legal claims.
Id., at 931.
A divided panel of the Court of Appeals for
the Ninth Circuit reversed and ordered the District Court to enter
a preliminary injunction.[
Footnote
8]
Raich v.
Ashcroft, 352 F. 3d 1222
(2003). The court found that respondents had “demonstrated a strong
likelihood of success on their claim that, as applied to them, the
CSA is an unconstitutional exercise of Congress’ Commerce Clause
authority.”
Id., at 1227. The Court of Appeals
distinguished prior Circuit cases upholding the CSA in the face of
Commerce Clause challenges by focusing on what it deemed to be the
“
separate and distinct class of activities” at issue in
this case: “the intrastate, noncommercial cultivation and
possession of cannabis for personal medical purposes as recommended
by a patient’s physician pursuant to valid California state law.”
Id., at 1228. The court found the latter class of
activities “different in kind from drug trafficking” because
interposing a physician’s recommendation raises different health
and safety concerns, and because “this limited use is clearly
distinct from the broader illicit drug market—as well as any
broader commercial market for medicinal marijuana—insofar as the
medicinal marijuana at issue in this case is not intended for, nor
does it enter, the stream of commerce.”
Ibid.
The majority placed heavy reliance on our
decisions in
United States v.
Lopez, 514
U. S. 549 (1995), and
United States v.
Morrison, 529
U. S. 598 (2000), as interpreted by recent Circuit precedent,
to hold that this separate class of purely local activities was
beyond the reach of federal power. In contrast, the dissenting
judge concluded that the CSA, as applied to respondents, was
clearly valid under
Lopez and
Morrison; moreover,
he thought it “simply impossible to distinguish the relevant
conduct surrounding the cultivation and use of the marijuana crop
at issue in this case from the cultivation and use of the wheat
crop that affected interstate commerce in
Wickard v.
Filburn.” 352 F. 3d, at 1235 (Beam, J., dissenting)
(citation omitted).
The obvious importance of the case prompted
our grant of certiorari.
542 U. S. 936 (2004).
The case is made difficult by respondents’ strong arguments that
they will suffer irreparable harm because, despite a congressional
finding to the contrary, marijuana does have valid therapeutic
purposes. The question before us, however, is not whether it is
wise to enforce the statute in these circumstances; rather, it is
whether Congress’ power to regulate interstate markets for
medicinal substances encompasses the portions of those markets that
are supplied with drugs produced and consumed locally. Well-settled
law controls our answer. The CSA is a valid exercise of federal
power, even as applied to the troubling facts of this case. We
accordingly vacate the judgment of the Court of Appeals.
II
Shortly after taking office in
1969, President Nixon declared a national “war on drugs.”[
Footnote 9] As the first campaign of
that war, Congress set out to enact legislation that would
consolidate various drug laws on the books into a comprehensive
statute, provide meaningful regulation over legitimate sources of
drugs to prevent diversion into illegal channels, and strengthen
law enforcement tools against the traffic in illicit
drugs.[
Footnote 10] That
effort culminated in the passage of the Comprehensive Drug Abuse
Prevention and Control Act of 1970, 84 Stat. 1236.
This was not, however, Congress’
first attempt to regulate the national market in drugs. Rather, as
early as 1906 Congress enacted federal legislation imposing
labeling regulations on medications and prohibiting the manufacture
or shipment of any adulterated or misbranded drug traveling in
interstate commerce.[
Footnote
11] Aside from these labeling restrictions, most domestic drug
regulations prior to 1970 generally came in the guise of revenue
laws, with the Department of the Treasury serving as the Federal
Government’s primary enforcer.[
Footnote 12] For example, the primary drug control law,
before being repealed by the passage of the CSA, was the Harrison
Narcotics Act of 1914, 38 Stat. 785 (repealed 1970). The Harrison
Act sought to exert control over the possession and sale of
narcotics, specifically cocaine and opiates, by requiring
producers, distributors, and purchasers to register with the
Federal Government, by assessing taxes against parties so
registered, and by regulating the issuance of
prescriptions.[
Footnote
13]
Marijuana itself was not significantly
regulated by the Federal Government until 1937 when accounts of
marijuana’s addictive qualities and physiological effects, paired
with dissatisfaction with enforcement efforts at state and local
levels, prompted Congress to pass the Marihuana Tax Act, Pub. L.
75–238, 50 Stat. 551 (repealed 1970).[
Footnote 14] Like the Harrison Act, the Marihuana Tax Act
did not outlaw the possession or sale of marijuana outright.
Rather, it imposed registration and reporting requirements for all
individuals importing, producing, selling, or dealing in marijuana,
and required the payment of annual taxes in addition to transfer
taxes whenever the drug changed hands.[
Footnote 15] Moreover, doctors wishing to prescribe
marijuana for medical purposes were required to comply with rather
burdensome administrative requirements.[
Footnote 16] Noncompliance exposed traffickers to
severe federal penalties, whereas compliance would often subject
them to prosecution under state law.[
Footnote 17] Thus, while the Marihuana Tax Act did not
declare the drug illegal
per se, the onerous
administrative requirements, the prohibitively expensive taxes, and
the risks attendant on compliance practically curtailed the
marijuana trade.
Then in 1970, after declaration of the
national “war on drugs,” federal drug policy underwent a
significant transformation. A number of noteworthy events
precipitated this policy shift. First, in
Leary v.
United States, 395 U. S. 6 (1969), this Court held
certain provisions of the Marihuana Tax Act and other narcotics
legislation unconstitutional. Second, at the end of his term,
President Johnson fundamentally reorganized the federal drug
control agencies. The Bureau of Narcotics, then housed in the
Department of Treasury, merged with the Bureau of Drug Abuse
Control, then housed in the Department of Health, Education, and
Welfare (HEW), to create the Bureau of Narcotics and Dangerous
Drugs, currently housed in the Department of Justice.[
Footnote 18] Finally, prompted by a
perceived need to consolidate the growing number of piecemeal drug
laws and to enhance federal drug enforcement powers, Congress
enacted the Comprehensive Drug Abuse Prevention and Control
Act.[
Footnote 19]
Title II of that Act, the CSA, repealed most
of the earlier antidrug laws in favor of a comprehensive regime to
combat the international and interstate traffic in illicit drugs.
The main objectives of the CSA were to conquer drug abuse and to
control the legitimate and illegitimate traffic in controlled
substances.[
Footnote 20]
Congress was particularly concerned with the need to prevent the
diversion of drugs from legitimate to illicit channels.[
Footnote 21]
To effectuate these goals, Congress devised a
closed regulatory system making it unlawful to manufacture,
distribute, dispense, or possess any controlled substance except in
a manner authorized by the CSA. 21 U. S. C. §§841(a)(1),
844(a). The CSA categorizes all controlled substances into five
schedules. §812. The drugs are grouped together based on their
accepted medical uses, the potential for abuse, and their
psychological and physical effects on the body. §§811, 812. Each
schedule is associated with a distinct set of controls regarding
the manufacture, distribution, and use of the substances listed
therein. §§821–830. The CSA and its implementing regulations set
forth strict requirements regarding registration, labeling and
packaging, production quotas, drug security, and recordkeeping.
Ibid. 21 CFR §1301
et seq. (2004).
In enacting the CSA, Congress classified
marijuana as a Schedule I drug. 21 U. S. C. §812(c). This
preliminary classification was based, in part, on the
recommendation of the Assistant Secretary of HEW “that marihuana be
retained within schedule I at least until the completion of certain
studies now underway.”[
Footnote
22] Schedule I drugs are categorized as such because of their
high potential for abuse, lack of any accepted medical use, and
absence of any accepted safety for use in medically supervised
treatment. §812(b)(1). These three factors, in varying gradations,
are also used to categorize drugs in the other four schedules. For
example, Schedule II substances also have a high potential for
abuse which may lead to severe psychological or physical
dependence, but unlike Schedule I drugs, they have a currently
accepted medical use. §812(b)(2). By classifying marijuana as a
Schedule I drug, as opposed to listing it on a lesser schedule, the
manufacture, distribution, or possession of marijuana became a
criminal offense, with the sole exception being use of the drug as
part of a Food and Drug Administration pre-approved research study.
§§823(f), 841(a)(1), 844(a); see also
United States v.
Oakland Cannabis Buyers’ Cooperative, 532 U. S. 483, 490
(2001).
The CSA provides for the periodic updating of
schedules and delegates authority to the Attorney General, after
consultation with the Secretary of Health and Human Services, to
add, remove, or transfer substances to, from, or between schedules.
§811. Despite considerable efforts to reschedule marijuana, it
remains a Schedule I drug.[
Footnote 23]
III
Respondents in this case do not
dispute that passage of the CSA, as part of the Comprehensive Drug
Abuse Prevention and Control Act, was well within Congress’
commerce power. Brief for Respondents 22, 38. Nor do they contend
that any provision or section of the CSA amounts to an
unconstitutional exercise of congressional authority. Rather,
respondents’ challenge is actually quite limited; they argue that
the CSA’s categorical prohibition of the manufacture and possession
of marijuana as applied to the intrastate manufacture and
possession of marijuana for medical purposes pursuant to California
law exceeds Congress’ authority under the Commerce Clause.
In assessing the validity of
congressional regulation, none of our Commerce Clause cases can be
viewed in isolation. As charted in considerable detail in
United States v.
Lopez, our understanding of the
reach of the Commerce Clause, as well as Congress’ assertion of
authority thereunder, has evolved over time.[
Footnote 24] The Commerce Clause emerged as the
Framers’ response to the central problem giving rise to the
Constitution itself: the absence of any federal commerce power
under the Articles of Confederation.[
Footnote 25] For the first century of our history, the
primary use of the Clause was to preclude the kind of
discriminatory state legislation that had once been
permissible.[
Footnote 26]
Then, in response to rapid industrial development and an
increasingly interdependent national economy, Congress “ushered in
a new era of federal regulation under the commerce power,”
beginning with the enactment of the Interstate Commerce Act in
1887, 24 Stat. 379, and the Sherman Antitrust Act in 1890, 26 Stat.
209, as amended, 15 U. S. C. §2
et seq.[Footnote 27]
Cases decided during that “new era,” which now
spans more than a century, have identified three general categories
of regulation in which Congress is authorized to engage under its
commerce power. First, Congress can regulate the channels of
interstate commerce.
Perez v.
United States,
402 U. S. 146,
150 (1971). Second, Congress has authority to regulate and protect
the instrumentalities of interstate commerce, and persons or things
in interstate commerce.
Ibid. Third, Congress has the
power to regulate activities that substantially affect interstate
commerce.
Ibid.
; NLRB v.
Jones &
Laughlin Steel Corp., 301 U. S. 1, 37 (1937).
Only the third category is implicated in the case at hand.
Our case law firmly establishes Congress’
power to regulate purely local activities that are part of an
economic “class of activities” that have a substantial effect on
interstate commerce. See,
e.g., Perez, 402 U. S., at 151;
Wickard v.
Filburn,
317
U. S. 111, 128–129 (1942). As we stated in
Wickard,
“even if appellee’s activity be local and though it may not be
regarded as commerce, it may still, whatever its nature, be reached
by Congress if it exerts a substantial economic effect on
interstate commerce.”
Id., at 125. We have never required
Congress to legislate with scientific exactitude. When Congress
decides that the “ ‘total incidence’ ” of a practice
poses a threat to a national market, it may regulate the entire
class. See
Perez, 402 U. S., at 154–155 (quoting
Westfall v.
United States,
274 U. S. 256, 259
(1927) (“[W]hen it is necessary in order to prevent an evil to make
the law embrace more than the precise thing to be prevented it may
do so”)). In this vein, we have reiterated that when “ ‘a
general regulatory statute bears a substantial relation to
commerce, the
de minimis character of individual instances
arising under that statute is of no consequence.’ ”
E.g., Lopez, 514 U. S., at 558 (emphasis deleted)
(quoting
Maryland v.
Wirtz,
392 U. S. 183, 196,
n. 27 (1968)).
Our decision in
Wickard, 317
U. S. 111, is of particular relevance. In
Wickard, we
upheld the application of regulations promulgated under the
Agricultural Adjustment Act of 1938, 52 Stat. 31, which were
designed to control the volume of wheat moving in interstate and
foreign commerce in order to avoid surpluses and consequent
abnormally low prices. The regulations established an allotment of
11.1 acres for Filburn’s 1941 wheat crop, but he sowed 23 acres,
intending to use the excess by consuming it on his own farm.
Filburn argued that even though we had sustained Congress’ power to
regulate the production of goods for commerce, that power did not
authorize “federal regulation [of] production not intended in any
part for commerce but wholly for consumption on the farm.”
Wickard, 317 U. S., at 118. Justice Jackson’s opinion for
a unanimous Court rejected this submission. He wrote:
“The effect of the statute before us is to restrict
the amount which may be produced for market and the extent as well
to which one may forestall resort to the market by producing to
meet his own needs. That appellee’s own contribution to the demand
for wheat may be trivial by itself is not enough to remove him from
the scope of federal regulation where, as here, his contribution,
taken together with that of many others similarly situated, is far
from trivial.”
Id., at 127–128.
Wickard thus establishes that Congress can
regulate purely intrastate activity that is not itself
“commercial,” in that it is not produced for sale, if it concludes
that failure to regulate that class of activity would undercut the
regulation of the interstate market in that commodity.
The similarities between this case and
Wickard are striking. Like the farmer in
Wickard,
respondents are cultivating, for home consumption, a fungible
commodity for which there is an established, albeit illegal,
interstate market.[
Footnote
28] Just as the Agricultural Adjustment Act was designed “to
control the volume [of wheat] moving in interstate and foreign
commerce in order to avoid surpluses …” and consequently control
the market price,
id., at 115, a primary purpose of the
CSA is to control the supply and demand of controlled substances in
both lawful and unlawful drug markets. See nn. 20–21,
supra. In
Wickard, we had no difficulty
concluding that Congress had a rational basis for believing that,
when viewed in the aggregate, leaving home-consumed wheat outside
the regulatory scheme would have a substantial influence on price
and market conditions. Here too, Congress had a rational basis for
concluding that leaving home-consumed marijuana outside federal
control would similarly affect price and market conditions.
More concretely, one concern prompting
inclusion of wheat grown for home consumption in the 1938 Act was
that rising market prices could draw such wheat into the interstate
market, resulting in lower market prices.
Wickard, 317 U.
S., at 128. The parallel concern making it appropriate to include
marijuana grown for home consumption in the CSA is the likelihood
that the high demand in the interstate market will draw such
marijuana into that market. While the diversion of homegrown wheat
tended to frustrate the federal interest in stabilizing prices by
regulating the volume of commercial transactions in the interstate
market, the diversion of homegrown marijuana tends to frustrate the
federal interest in eliminating commercial transactions in the
interstate market in their entirety. In both cases, the regulation
is squarely within Congress’ commerce power because production of
the commodity meant for home consumption, be it wheat or marijuana,
has a substantial effect on supply and demand in the national
market for that commodity.[
Footnote 29]
Nonetheless, respondents suggest that
Wickard differs from this case in three respects: (1) the
Agricultural Adjustment Act, unlike the CSA, exempted small farming
operations; (2)
Wickard involved a “quintessential
economic activity”—a commercial farm—whereas respondents do not
sell marijuana; and (3) the
Wickard record made it clear
that the aggregate production of wheat for use on farms had a
significant impact on market prices. Those differences, though
factually accurate, do not diminish the precedential force of this
Court’s reasoning.
The fact that Wickard’s own impact on the
market was “trivial by itself ” was not a sufficient reason
for removing him from the scope of federal regulation. 317 U. S.,
at 127. That the Secretary of Agriculture elected to exempt even
smaller farms from regulation does not speak to his power to
regulate all those whose aggregated production was significant, nor
did that fact play any role in the Court’s analysis. Moreover, even
though Wickard was indeed a commercial farmer, the activity he was
engaged in—the cultivation of wheat for home consumption—was not
treated by the Court as part of his commercial farming
operation.[
Footnote 30] And
while it is true that the record in the
Wickard case
itself established the causal connection between the production for
local use and the national market, we have before us findings by
Congress to the same effect.
Findings in the introductory sections of the
CSA explain why Congress deemed it appropriate to encompass local
activities within the scope of the CSA. See n. 20,
supra. The submissions of the parties and the numerous
amici all seem to agree that the national, and
international, market for marijuana has dimensions that are fully
comparable to those defining the class of activities regulated by
the Secretary pursuant to the 1938 statute.[
Footnote 31] Respondents nonetheless insist
that the CSA cannot be constitutionally applied to their activities
because Congress did not make a specific finding that the
intrastate cultivation and possession of marijuana for medical
purposes based on the recommendation of a physician would
substantially affect the larger interstate marijuana market. Be
that as it may, we have never required Congress to make
particularized findings in order to legislate, see
Lopez,
514 U. S., at 562;
Perez, 402 U. S., at 156, absent a
special concern such as the protection of free speech, see,
e.g., Turner Broadcasting System, Inc. v.
FCC,
512 U.
S. 622, 664–668 (1994) (plurality opinion). While congressional
findings are certainly helpful in reviewing the substance of a
congressional statutory scheme, particularly when the connection to
commerce is not self-evident, and while we will consider
congressional findings in our analysis when they are available, the
absence of particularized findings does not call into question
Congress’ authority to legislate.[
Footnote 32]
In assessing the scope of Congress’ authority
under the Commerce Clause, we stress that the task before us is a
modest one. We need not determine whether respondents’ activities,
taken in the aggregate, substantially affect interstate commerce in
fact, but only whether a “rational basis” exists for so concluding.
Lopez, 514 U. S., at 557; see also
Hodel v.
Virginia Surface Mining & Reclamation Assn., Inc.,
452 U. S. 264,
276–280 (1981);
Perez, 402 U. S., at 155–156;
Katzenbach v.
McClung,
379 U. S. 294, 299–301
(1964);
Heart of Atlanta Motel, Inc. v.
United
States,
379 U.
S. 241, 252–253 (1964). Given the enforcement difficulties that
attend distinguishing between marijuana cultivated locally and
marijuana grown elsewhere, 21 U. S. C. §801(5), and concerns
about diversion into illicit channels,[
Footnote 33] we have no difficulty concluding that
Congress had a rational basis for believing that failure to
regulate the intrastate manufacture and possession of marijuana
would leave a gaping hole in the CSA. Thus, as in
Wickard,
when it enacted comprehensive legislation to regulate the
interstate market in a fungible commodity, Congress was acting well
within its authority to “make all Laws which shall be necessary and
proper” to “regulate Commerce … among the several States.” U. S.
Const., Art. I, §8. That the regulation ensnares some purely
intrastate activity is of no moment. As we have done many times
before, we refuse to excise individual components of that larger
scheme.
IV
To support their contrary
submission, respondents rely heavily on two of our more recent
Commerce Clause cases. In their myopic focus, they overlook the
larger context of modern-era Commerce Clause jurisprudence
preserved by those cases. Moreover, even in the narrow prism of
respondents’ creation, they read those cases far too broadly.
Those two cases, of course, are
Lopez,
514
U. S. 549, and
Morrison,
529
U. S. 598. As an initial matter, the statutory challenges at
issue in those cases were markedly different from the challenge
respondents pursue in the case at hand. Here, respondents ask us to
excise individual applications of a concededly valid statutory
scheme. In contrast, in both
Lopez and
Morrison,
the parties asserted that a particular statute or provision fell
outside Congress’ commerce power in its entirety. This distinction
is pivotal for we have often reiterated that “[w]here the class of
activities is regulated and that class is within the reach of
federal power, the courts have no power ‘to excise, as trivial,
individual instances’ of the class.”
Perez, 402 U. S., at
154 (emphasis deleted) (quoting
Wirtz, 392 U. S., at 193);
see also
Hodel, 452 U. S., at 308.
At issue in
Lopez,
514
U. S. 549, was the validity of the Gun-Free School Zones Act of
1990, which was a brief, single-subject statute making it a crime
for an individual to possess a gun in a school zone. 104 Stat.
4844–4845, 18 U. S. C. §922(q)(1)(A). The Act did not regulate
any economic activity and did not contain any requirement that the
possession of a gun have any connection to past interstate activity
or a predictable impact on future commercial activity.
Distinguishing our earlier cases holding that comprehensive
regulatory statutes may be validly applied to local conduct that
does not, when viewed in isolation, have a significant impact on
interstate commerce, we held the statute invalid. We explained:
“Section 922(q) is a criminal statute that by its
terms has nothing to do with ‘commerce’ or any sort of economic
enterprise, however broadly one might define those terms. Section
922(q) is not an essential part of a larger regulation of economic
activity, in which the regulatory scheme could be undercut unless
the intrastate activity were regulated. It cannot, therefore, be
sustained under our cases upholding regulations of activities that
arise out of or are connected with a commercial transaction, which
viewed in the aggregate, substantially affects interstate
commerce.” 514 U. S., at 561.
The statutory scheme that the
Government is defending in this litigation is at the opposite end
of the regulatory spectrum. As explained above, the CSA, enacted in
1970 as part of the Comprehensive Drug Abuse Prevention and Control
Act, 84 Stat. 1242–1284, was a lengthy and detailed statute
creating a comprehensive framework for regulating the production,
distribution, and possession of five classes of “controlled
substances.” Most of those substances—those listed in Schedules II
through V—“have a useful and legitimate medical purpose and are
necessary to maintain the health and general welfare of the
American people.” 21 U. S. C. §801(1). The regulatory scheme
is designed to foster the beneficial use of those medications, to
prevent their misuse, and to prohibit entirely the possession or
use of substances listed in Schedule I, except as a part of a
strictly controlled research project.
While the statute provided for the periodic
updating of the five schedules, Congress itself made the initial
classifications. It identified 42 opiates, 22 opium derivatives,
and 17 hallucinogenic substances as Schedule I drugs. 84 Stat.
1248. Marijuana was listed as the 10th item in the third
subcategory. That classification, unlike the discrete prohibition
established by the Gun-Free School Zones Act of 1990, was merely
one of many “essential part[s] of a larger regulation of economic
activity, in which the regulatory scheme could be undercut unless
the intrastate activity were regulated.”
Lopez, 514 U. S.,
at 561.[
Footnote 34] Our
opinion in
Lopez casts no doubt on the validity of such a
program.
Nor does this Court’s holding in
Morrison,
529
U. S. 598. The Violence Against Women Act of 1994, 108 Stat.
1902, created a federal civil remedy for the victims of
gender-motivated crimes of violence. 42 U. S. C. §13981. The
remedy was enforceable in both state and federal courts, and
generally depended on proof of the violation of a state law.
Despite congressional findings that such crimes had an adverse
impact on interstate commerce, we held the statute unconstitutional
because, like the statute in
Lopez, it did not regulate
economic activity. We concluded that “the noneconomic, criminal
nature of the conduct at issue was central to our decision” in
Lopez, and that our prior cases had identified a clear
pattern of analysis: “ ‘Where economic activity substantially
affects interstate commerce, legislation regulating that activity
will be sustained.’ ”[
Footnote 35]
Morrison, 529 U. S., at 610.
Unlike those at issue in
Lopez and
Morrison, the activities regulated by the CSA are
quintessentially economic. “Economics” refers to “the production,
distribution, and consumption of commodities.” Webster’s Third New
International Dictionary 720 (1966). The CSA is a statute that
regulates the production, distribution, and consumption of
commodities for which there is an established, and lucrative,
interstate market. Prohibiting the intrastate possession or
manufacture of an article of commerce is a rational (and commonly
utilized) means of regulating commerce in that product.[
Footnote 36] Such prohibitions
include specific decisions requiring that a drug be withdrawn from
the market as a result of the failure to comply with regulatory
requirements as well as decisions excluding Schedule I drugs
entirely from the market. Because the CSA is a statute that
directly regulates economic, commercial activity, our opinion in
Morrison casts no doubt on its constitutionality.
The Court of Appeals was able to conclude
otherwise only by isolating a “separate and distinct” class of
activities that it held to be beyond the reach of federal power,
defined as “the intrastate, noncommercial cultivation, possession
and use of marijuana for personal medical purposes on the advice of
a physician and in accordance with state law.” 352 F. 3d, at
1229. The court characterized this class as “different in kind from
drug trafficking.”
Id., at 1228. The differences between
the members of a class so defined and the principal traffickers in
Schedule I substances might be sufficient to justify a policy
decision exempting the narrower class from the coverage of the CSA.
The question, however, is whether Congress’ contrary policy
judgment,
i.e., its decision to include this narrower
“class of activities” within the larger regulatory scheme, was
constitutionally deficient. We have no difficulty concluding that
Congress acted rationally in determining that none of the
characteristics making up the purported class, whether viewed
individually or in the aggregate, compelled an exemption from the
CSA; rather, the subdivided class of activities defined by the
Court of Appeals was an essential part of the larger regulatory
scheme.
First, the fact that marijuana is used “for
personal medical purposes on the advice of a physician” cannot
itself serve as a distinguishing factor. 352 F. 3d, at 1229.
The CSA designates marijuana as contraband for
any
purpose; in fact, by characterizing marijuana as a Schedule I drug,
Congress expressly found that the drug has no acceptable medical
uses. Moreover, the CSA is a comprehensive regulatory regime
specifically designed to regulate which controlled substances can
be utilized for medicinal purposes, and in what manner. Indeed,
most of the substances classified in the CSA “have a useful and
legitimate medical purpose.” 21 U. S. C. §801(1). Thus, even
if respondents are correct that marijuana does have accepted
medical uses and thus should be redesignated as a lesser schedule
drug,[
Footnote 37] the CSA
would still impose controls beyond what is required by California
law. The CSA requires manufacturers, physicians, pharmacies, and
other handlers of controlled substances to comply with statutory
and regulatory provisions mandating registration with the DEA,
compliance with specific production quotas, security controls to
guard against diversion, recordkeeping and reporting obligations,
and prescription requirements. See 21 U. S. C. §§821–830; 21
CFR §1301
et seq. (2004). Furthermore, the dispensing of
new drugs, even when doctors approve their use, must await federal
approval.
United States v.
Rutherford,
442 U. S. 544 (1979).
Accordingly, the mere fact that marijuana—like virtually every
other controlled substance regulated by the CSA—is used for
medicinal purposes cannot possibly serve to distinguish it from the
core activities regulated by the CSA.
Nor can it serve as an “objective marke[r]” or
“objective facto[r]” to arbitrarily narrow the relevant class as
the dissenters suggest,
post, at 6 (O’Connor, J.,
dissenting);
post, at 12 (Thomas, J., dissenting). More
fundamentally, if, as the principal dissent contends, the personal
cultivation, possession, and use of marijuana for medicinal
purposes is beyond the “ ‘outer limits’ of Congress’ Commerce
Clause authority,”
post, at 1 (O’Connor, J., dissenting),
it must also be true that such personal use of marijuana (or any
other homegrown drug) for recreational purposes is also beyond
those “ ‘outer limits,’ ” whether or not a State elects
to authorize or even regulate such use. Justice Thomas’ separate
dissent suffers from the same sweeping implications. That is, the
dissenters’ rationale logically extends to place
any
federal regulation (including quality, prescription, or quantity
controls) of
any locally cultivated and possessed
controlled substance for
any purpose beyond the
“ ‘outer limits’ ” of Congress’ Commerce Clause
authority. One need not have a degree in economics to understand
why a nationwide exemption for the vast quantity of marijuana (or
other drugs) locally cultivated for personal use (which presumably
would include use by friends, neighbors, and family members) may
have a substantial impact on the interstate market for this
extraordinarily popular substance. The congressional judgment that
an exemption for such a significant segment of the total market
would undermine the orderly enforcement of the entire regulatory
scheme is entitled to a strong presumption of validity. Indeed,
that judgment is not only rational, but “visible to the naked eye,”
Lopez, 514 U. S., at 563, under any commonsense appraisal
of the probable consequences of such an open-ended exemption.
Second, limiting the activity to marijuana
possession and cultivation “in accordance with state law” cannot
serve to place respondents’ activities beyond congressional reach.
The Supremacy Clause unambiguously provides that if there is any
conflict between federal and state law, federal law shall prevail.
It is beyond peradventure that federal power over commerce is
“ ‘superior to that of the States to provide for the welfare
or necessities of their inhabitants,’ ” however legitimate or
dire those necessities may be.
Wirtz, 392 U. S., at 196
(quoting
Sanitary Dist. of Chicago v.
United
States,
266 U.
S. 405, 426 (1925)). See also 392 U. S., at 195–196;
Wickard, 317 U. S., at 124 (“ ‘[N]o form of state
activity can constitutionally thwart the regulatory power granted
by the commerce clause to Congress’ ”). Just as state
acquiescence to federal regulation cannot expand the bounds of the
Commerce Clause, see,
e.g.,
Morrison, 529 U. S.,
at 661–662 (Breyer, J., dissenting) (noting that 38 States
requested federal intervention), so too state action cannot
circumscribe Congress’ plenary commerce power. See
United
States v.
Darby,
312 U. S. 100, 114
(1941) (“That power can neither be enlarged nor diminished by the
exercise or non-exercise of state power”).[
Footnote 38]
Respondents acknowledge this proposition, but
nonetheless contend that their activities were not “an essential
part of a larger regulatory scheme” because they had been “isolated
by the State of California, and [are] policed by the State of
California,” and thus remain “entirely separated from the market.”
Tr. of Oral Arg. 27. The dissenters fall prey to similar reasoning.
See n. 38,
supra this page. The notion that California law
has surgically excised a discrete activity that is hermetically
sealed off from the larger interstate marijuana market is a dubious
proposition, and, more importantly, one that Congress could have
rationally rejected.
Indeed, that the California exemptions will
have a significant impact on both the supply and demand sides of
the market for marijuana is not just “plausible” as the principal
dissent concedes,
post, at 16 (O’Connor, J., dissenting),
it is readily apparent. The exemption for physicians provides them
with an economic incentive to grant their patients permission to
use the drug. In contrast to most prescriptions for legal drugs,
which limit the dosage and duration of the usage, under California
law the doctor’s permission to recommend marijuana use is
open-ended. The authority to grant permission whenever the doctor
determines that a patient is afflicted with “any other illness for
which marijuana provides relief,” Cal. Health & Safety Code
Ann. §11362.5(b)(1)(A) (West Supp. 2005), is broad enough to allow
even the most scrupulous doctor to conclude that some recreational
uses would be therapeutic.[
Footnote 39] And our cases have taught us that there are
some unscrupulous physicians who overprescribe when it is
sufficiently profitable to do so.[
Footnote 40]
The exemption for cultivation by patients and
caregivers can only increase the supply of marijuana in the
California market.[
Footnote
41] The likelihood that all such production will promptly
terminate when patients recover or will precisely match the
patients’ medical needs during their convalescence seems remote;
whereas the danger that excesses will satisfy some of the
admittedly enormous demand for recreational use seems
obvious.[
Footnote 42]
Moreover, that the national and international narcotics trade has
thrived in the face of vigorous criminal enforcement efforts
suggests that no small number of unscrupulous people will make use
of the California exemptions to serve their commercial ends
whenever it is feasible to do so.[
Footnote 43] Taking into account the fact that California
is only one of at least nine States to have authorized the medical
use of marijuana, a fact Justice O’Connor’s dissent conveniently
disregards in arguing that the demonstrated effect on commerce
while admittedly “plausible” is ultimately “unsubstantiated,”
post, at 14, 16, Congress could have rationally concluded
that the aggregate impact on the national market of all the
transactions exempted from federal supervision is unquestionably
substantial.
So, from the “separate and distinct” class of
activities identified by the Court of Appeals (and adopted by the
dissenters), we are left with “the intrastate, noncommercial
cultivation, possession and use of marijuana.” 352 F. 3d, at
1229. Thus the case for the exemption comes down to the claim that
a locally cultivated product that is used domestically rather than
sold on the open market is not subject to federal regulation. Given
the findings in the CSA and the undisputed magnitude of the
commercial market for marijuana, our decisions in
Wickard
v.
Filburn and the later cases endorsing its reasoning
foreclose that claim.
V
Respondents also raise a
substantive due process claim and seek to avail themselves of the
medical necessity defense. These theories of relief were set forth
in their complaint but were not reached by the Court of Appeals. We
therefore do not address the question whether judicial relief is
available to respondents on these alternative bases. We do note,
however, the presence of another avenue of relief. As the Solicitor
General confirmed during oral argument, the statute authorizes
procedures for the reclassification of Schedule I drugs. But
perhaps even more important than these legal avenues is the
democratic process, in which the voices of voters allied with these
respondents may one day be heard in the halls of Congress. Under
the present state of the law, however, the judgment of the Court of
Appeals must be vacated. The case is remanded for further
proceedings consistent with this opinion.
It is so ordered.
Footnote 1
See Alaska Stat. §§11.71.090,
17.37.010–17.37.080 (Lexis 2004); Colo. Const., Art. XVIII, §14,
Colo. Rev. Stat. §18–18–406.3 (Lexis 2004); Haw. Rev. Stat.
§§329–121 to 329–128 (2004 Cum. Supp.); Me. Rev. Stat. Ann., Tit.
22, §2383–B(5) (West 2004); Nev. Const., Art. 4, §38, Nev. Rev.
Stat. §§453A.010–453A.810 (2003); Ore. Rev. Stat. §§475.300–475.346
(2003); Vt. Stat. Ann., Tit. 18, §§4472–4474d (Supp. 2004); Wash.
Rev. Code §§69.51.010–69.51.080 (2004); see also Ariz. Rev. Stat.
Ann. §13–3412.01 (West Supp. 2004) (voter initiative permitting
physicians to prescribe Schedule I substances for medical purposes
that was purportedly repealed in 1997, but the repeal was rejected
by voters in 1998). In November 2004, Montana voters approved
Initiative 148, adding to the number of States authorizing the use
of marijuana for medical purposes.
Footnote 2
1913 Cal. Stats. ch. 324, §8
a; see
also Gieringer, The Origins of Cannabis Prohibition in California,
Contemporary Drug Problems, 21–23 (rev. 2005).
Footnote 3
Cal. Health & Safety Code Ann. §11362.5
(West Supp. 2005). The California Legislature recently enacted
additional legislation supplementing the Compassionate Use Act.
§§11362.7–11362.9 (West Supp. 2005).
Footnote 4
“The people of the State of California hereby
find and declare that the purposes of the Compassionate Use Act of
1996 are as follows:
“(A) To ensure that seriously ill Californians
have the right to obtain and use marijuana for medical purposes
where that medical use is deemed appropriate and has been
recommended by a physician who has determined that the person’s
health would benefit from the use of marijuana in the treatment of
cancer, anorexia, AIDS, chronic pain, spasticity, glaucoma,
arthritis, migraine, or any other illness for which marijuana
provides relief.
“(B) To ensure that patients and their primary
caregivers who obtain and use marijuana for medical purposes upon
the recommendation of a physician are not subject to criminal
prosecution or sanction.
“(C) To encourage the federal and state
governments to implement a plan to provide for the safe and
affordable distribution of marijuana to all patients in medical
need of marijuana.” §11362.5(b)(1) (West Supp. 2005).
Footnote 5
“Notwithstanding any other provision of law,
no physician in this state shall be punished, or denied any right
or privilege, for having recommended marijuana to a patient for
medical purposes.” §11362.5(c) (West Supp. 2005).
Footnote 6
“Section 11357, relating to the possession of
marijuana, and Section 11358, relating to the cultivation of
marijuana, shall not apply to a patient, or to a patient’s primary
caregiver, who possesses or cultivates marijuana for the personal
medical purposes of the patient upon the written or oral
recommendation or approval of a physician.” §11362.5(d) (West Supp.
2005).
Footnote 7
§11362.5(e) (West Supp. 2005).
Footnote 8
On remand, the District Court entered a
preliminary injunction enjoining petitioners “ ‘from arresting
or prosecuting Plaintiffs Angel McClary Raich and Diane Monson,
seizing their medical cannabis, forfeiting their property, or
seeking civil or administrative sanctions against them with respect
to the intrastate, non-commercial cultivation, possession, use, and
obtaining without charge of cannabis for personal medical purposes
on the advice of a physician and in accordance with state law, and
which is not used for distribution, sale, or exchange.’ ”
Brief for Petitioners 9.
Footnote 9
See D. Musto & P. Korsmeyer, The Quest
for Drug Control 60 (2002) (hereinafter Musto & Korsmeyer).
Footnote 10
H. R. Rep. No. 91–1444, pt. 2,
p. 22 (1970) (hereinafter H. R. Rep.); 26 Congressional
Quarterly Almanac 531 (1970) (hereinafter Almanac); Musto &
Korsmeyer 56–57.
Footnote 11
Pure Food and Drug Act of 1906, ch. 3915, 34
Stat. 768, repealed by Act of June 25, 1938, ch. 675, §902(a), 52
Stat. 1059.
Footnote 12
See
United States v.
Doremus, 249 U. S. 86 (1919);
Leary v.
United States, 395 U. S. 6, 14–16 (1969).
Footnote 13
See
Doremus, 249 U. S., at
90–93.
Footnote 14
R. Bonnie & C. Whitebread, The Marijuana
Conviction 154–174 (1999); L. Grinspoon & J. Bakalar,
Marihuana, the Forbidden Medicine 7–8 (rev. ed. 1997) (hereinafter
Grinspoon & Bakalar). Although this was the Federal
Government’s first attempt to regulate the marijuana trade, by this
time all States had in place some form of legislation regulating
the sale, use, or possession of marijuana. R. Isralowitz, Drug Use,
Policy, and Management 134 (2d ed. 2002).
Footnote 15
Leary, 395 U. S., at 14–16.
Footnote 16
Grinspoon & Bakalar 8.
Footnote 17
Leary, 395 U. S., at 16–18.
Footnote 18
Musto & Korsmeyer 32–35; 26 Almanac 533.
In 1973, the Bureau of Narcotics and Dangerous Drugs became the
Drug Enforcement Administration (DEA). See Reorg. Plan No. 2 of
1973, §1, 28 CFR §0.100 (1973).
Footnote 19
The Comprehensive Drug Abuse Prevention and
Control Act of 1970 consists of three titles. Title I relates to
the prevention and treatment of narcotic addicts through HEW (now
the Department of Health and Human Services). 84 Stat. 1238. Title
II, as discussed in more detail above, addresses drug control and
enforcement as administered by the Attorney General and the DEA.
Id., at 1242. Title III concerns the import and export of
controlled substances.
Id., at 1285.
Footnote 20
In particular, Congress made the following
findings:
“(1) Many of the drugs included within this
subchapter have a useful and legitimate medical purpose and are
necessary to maintain the health and general welfare of the
American people.
“(2) The illegal importation, manufacture,
distribution, and possession and improper use of controlled
substances have a substantial and detrimental effect on the health
and general welfare of the American people.
“(3) A major portion of the traffic in
controlled substances flows through interstate and foreign
commerce. Incidents of the traffic which are not an integral part
of the interstate or foreign flow, such as manufacture, local
distribution, and possession, nonetheless have a substantial and
direct effect upon interstate commerce because—
“(A) after manufacture, many
controlled substances are transported in interstate commerce,
“(B) controlled substances
distributed locally usually have been transported in interstate
commerce immediately before their distribution, and
“(C) controlled substances
possessed commonly flow through interstate commerce immediately
prior to such possession.
“(4) Local distribution and possession of
controlled substances contribute to swelling the interstate traffic
in such substances.
“(5) Controlled substances manufactured and
distributed intrastate cannot be differentiated from controlled
substances manufactured and distributed interstate. Thus, it is not
feasible to distinguish, in terms of controls, between controlled
substances manufactured and distributed interstate and controlled
substances manufactured and distributed intrastate.
“(6) Federal control of the intrastate
incidents of the traffic in controlled substances is essential to
the effective control of the interstate incidents of such traffic.”
21 U. S. C. §§801(1)–(6).
Footnote 21
See
United States v.
Moore,
423 U. S. 122, 135 (1975); see
also H. R. Rep., at 22.
Footnote 22
H. R. Rep.
, at 61 (quoting
letter from Roger E. Egeberg, M. D. to Hon. Harley O. Staggers
(Aug. 14, 1970)).
Footnote 23
Starting in 1972, the National Organization
for the Reform of Marijuana Laws (NORML) began its campaign to
reclassify marijuana. Grinspoon & Bakalar 13–17. After some
fleeting success in 1988 when an Administrative Law Judge (ALJ)
declared that the DEA would be acting in an “unreasonable,
arbitrary, and capricious” manner if it continued to deny marijuana
access to seriously ill patients, and concluded that it should be
reclassified as a Schedule III substance,
Grinspoon v.
DEA, 828 F. 2d 881, 883–884 (CA1 1987), the campaign
has proved unsuccessful. The DEA Administrator did not endorse the
ALJ’s findings, 54 Fed. Reg. 53767 (1989), and since that time has
routinely denied petitions to reschedule the drug, most recently in
2001. 66 Fed. Reg. 20038 (2001). The Court of Appeals for the
District of Columbia Circuit has reviewed the petition to
reschedule marijuana on five separate occasions over the course of
30 years, ultimately upholding the Administrator’s final order. See
Alliance for Cannabis Therapeutics v.
DEA, 15
F. 3d 1131, 1133 (1994).
Footnote 24
United States v.
Lopez,
514
U. S. 549, 552–558 (1995);
id., at 568–574 (Kennedy,
J., concurring);
id., at 604–607 (Souter, J.,
dissenting).
Footnote 25
See
Gibbons v.
Ogden, 9
Wheat. 1, 224 (1824) (opinion of Johnson, J.); Stern, That Commerce
Which Concerns More States Than One, 47 Harv. L. Rev. 1335,
1337, 1340–1341 (1934); G. Gunther, Constitutional Law 127 (9th ed.
1975).
Footnote 26
See
Lopez, 514 U. S., at 553–554;
id., at 568–569 (Kennedy, J., concurring); see also
Granholm v.
Heald, 544 U. S. __, __ (2005) (slip
op., at 8–9).
Footnote 27
Lopez, 514 U. S., at 554; see also
Wickard v.
Filburn,
317
U. S. 111, 121 (1942) (“It was not until 1887, with the
enactment of the Interstate Commerce Act, that the interstate
commerce power began to exert positive influence in American law
and life. This first important federal resort to the commerce power
was followed in 1890 by the Sherman Anti-Trust Act and, thereafter,
mainly after 1903, by many others. These statutes ushered in new
phases of adjudication, which required the Court to approach the
interpretation of the Commerce Clause in the light of an actual
exercise by Congress of its power thereunder” (footnotes
omitted)).
Footnote 28
Even respondents acknowledge the existence of
an illicit market in marijuana; indeed, Raich has personally
participated in that market, and Monson expresses a willingness to
do so in the future. App. 59, 74, 87. See also
Department of
Revenue of Mont. v.
Kurth Ranch,
511 U. S. 767, 770, 774,
n. 12, and 780, n. 17 (1994) (discussing the “market
value” of marijuana);
id., at 790 (Rehnquist, C. J.,
dissenting);
id., at 792 (O’Connor, J., dissenting);
Whalen v.
Roe,
429 U. S. 589, 591
(1977) (addressing prescription drugs “for which there is both a
lawful and an unlawful market”);
Turner v.
United
States,
396 U.
S. 398, 417, n. 33 (1970) (referring to the purchase of
drugs on the “retail market”).
Footnote 29
To be sure, the wheat market is a lawful
market that Congress sought to protect and stabilize, whereas the
marijuana market is an unlawful market that Congress sought to
eradicate. This difference, however, is of no constitutional
import. It has long been settled that Congress’ power to regulate
commerce includes the power to prohibit commerce in a particular
commodity.
Lopez, 514 U. S., at 571 (Kennedy, J.,
concurring) (“In the
Lottery Case,
188 U. S. 321 (1903),
the Court rejected the argument that Congress lacked [the] power to
prohibit the interstate movement of lottery tickets because it had
power only to regulate, not to prohibit”); see also
Wickard, 317 U. S., at 128 (“The stimulation of commerce
is a use of the regulatory function quite as definitely as
prohibitions or restrictions thereon”).
Footnote 30
See
Wickard, 317 U. S., at 125
(recognizing that Wickard’s activity “may not be regarded as
commerce”).
Footnote 31
The Executive Office of the President has
estimated that in 2000 American users spent $10.5
billion
on the purchase of marijuana. Office of Nat. Drug Control Policy,
Marijuana Fact Sheet 5 (Feb. 2004), available at
http://www.whitehousedrugpolicy.gov/publications/factsht/marijuana/
(all Internet materials as visited June 2, 2005, and available in
Clerk of Court’s case file).
Footnote 32
Moreover, as discussed in more detail above,
Congress did make findings regarding the effects of intrastate drug
activity on interstate commerce. See n. 20,
supra.
Indeed, even the Court of Appeals found that those findings
“weigh[ed] in favor” of upholding the constitutionality of the CSA.
352 F. 3d 1222, 1232 (CA9 2003) (case below). The dissenters,
however, would impose a new and heightened burden on Congress
(unless the litigants can garner evidence sufficient to cure
Congress’ perceived “inadequa[cies]”)—that legislation must contain
detailed findings proving that each activity regulated within a
comprehensive statute is essential to the statutory scheme.
Post, at 13–15 (O’Connor, J., dissenting);
post,
at 8 (Thomas, J., dissenting). Such an exacting requirement is not
only unprecedented, it is also impractical. Indeed, the principal
dissent’s critique of Congress for “not even” including
“declarations” specific to marijuana is particularly unpersuasive
given that the CSA initially identified 80 other substances subject
to regulation as Schedule I drugs, not to mention those categorized
in Schedules II–V.
Post, at 14 (O’Connor, J.,
dissenting)
. Surely, Congress cannot be expected (and
certainly should not be required) to include specific findings on
each and every substance contained therein in order to satisfy the
dissenters’ unfounded skepticism.
Footnote 33
See n. 21,
supra (citing
sources that evince Congress’ particular concern with the diversion
of drugs from legitimate to illicit channels).
Footnote 34
The principal dissent asserts that by
“[s]eizing upon our language in
Lopez,”
post, at
5 (opinion of O’Connor, J.),
i.e., giving effect to our
well-established case law, Congress will now have an incentive to
legislate broadly. Even putting aside the political checks that
would generally curb Congress’ power to enact a broad and
comprehensive scheme for the purpose of targeting purely local
activity, there is no suggestion that the CSA constitutes the type
of “evasive” legislation the dissent fears, nor could such an
argument plausibly be made.
Post, at 6 (O’Connor, J.,
dissenting)
.
Footnote 35
Lopez, 514 U. S., at 560; see also
id., at 573–574 (Kennedy, J., concurring) (stating that
Lopez did not alter our “practical conception of
commercial regulation” and that Congress may “regulate in the
commercial sphere on the assumption that we have a single market
and a unified purpose to build a stable national economy”).
Footnote 36
See 16 U. S. C. §668(a) (bald and golden
eagles); 18 U. S. C. §175(a) (biological weapons); §831(a)
(nuclear material); §842(n)(1) (certain plastic explosives);
§2342(a) (contraband cigarettes).
Footnote 37
We acknowledge that evidence proffered by
respondents in this case regarding the effective medical uses for
marijuana, if found credible after trial, would cast serious doubt
on the accuracy of the findings that require marijuana to be listed
in Schedule I. See,
e.g., Institute of Medicine, Marijuana
and Medicine: Assessing the Science Base 179 (J. Joy, S. Watson,
& J. Benson eds. 1999) (recognizing that “[s]cientific data
indicate the potential therapeutic value of cannabinoid drugs,
primarily THC [Tetrahydrocannabinol] for pain relief, control of
nausea and vomiting, and appetite stimulation”); see also
Conant v.
Walters, 309 F. 3d 629, 640–643
(CA9 2002) (Kozinski, J., concurring) (chronicling medical studies
recognizing valid medical uses for marijuana and its derivatives).
But the possibility that the drug may be reclassified in the future
has no relevance to the question whether Congress now has the power
to regulate its production and distribution. Respondents’
submission, if accepted, would place all homegrown medical
substances beyond the reach of Congress’ regulatory
jurisdiction.
Footnote 38
That is so even if California’s current
controls (enacted eight years after the Compassionate Use Act was
passed) are “[e]ffective,” as the dissenters would have us blindly
presume,
post, at 15 (O’Connor, J., dissenting);
post, at 6, 12 (Thomas, J., dissenting). California’s
decision (made 34 years after the CSA was enacted) to impose
“stric[t] controls” on the “cultivation and possession of marijuana
for medical purposes,”
post, at 6 (Thomas, J.,
dissenting), cannot retroactively divest Congress of its authority
under the Commerce Clause. Indeed, Justice Thomas’ urgings to the
contrary would turn the Supremacy Clause on its head, and would
resurrect limits on congressional power that have long since been
rejected. See
post, at 8 (Scalia, J., concurring in
judgment) (quoting
McCulloch v.
Maryland, 4
Wheat. 316, 424 (1819)) (“ ‘To impose on [Congress] the
necessity of resorting to means which it cannot control, which
another government may furnish or withhold, would render its course
precarious, the result of its measures uncertain, and create a
dependence on other governments, which might disappoint its most
important designs, and is incompatible with the language of the
constitution’ ”).
Moreover, in addition to casting aside more than a century of
this Court’s Commerce Clause jurisprudence, it is noteworthy that
Justice Thomas’ suggestion that States possess the power to dictate
the extent of Congress’ commerce power would have far-reaching
implications beyond the facts of this case. For example, under his
reasoning, Congress would be equally powerless to regulate, let
alone prohibit, the intrastate possession, cultivation, and use of
marijuana for
recreational purposes, an activity which all
States “strictly contro[l].” Indeed, his rationale seemingly would
require Congress to cede its constitutional power to regulate
commerce whenever a State opts to exercise its “traditional police
powers to define the criminal law and to protect the health,
safety, and welfare of their citizens.”
Post, at 9–10
(dissenting opinion).
Footnote 39
California’s Compassionate Use Act has since
been amended, limiting the catchall category to “[a]ny other
chronic or persistent medical symptom that either: …
[s]ubstantially limits the ability of the person to conduct one or
more major life activities as defined” in the Americans with
Disabilities Act of 1990, or “[i]f not alleviated, may cause
serious harm to the patient’s safety or physical or mental health.”
Cal. Health & Safety Code Ann. §§11362.7(h)(12)(A) to (12)(B)
(West Supp. 2005).
Footnote 40
See,
e.g., United States v.
Moore, 423 U. S. 122 (1975);
United
States v.
Doremus,
249 U. S. 86 (1919).
Footnote 41
The state policy allows patients to possess
up to eight ounces of dried marijuana, and to cultivate up to 6
mature or 12 immature plants. Cal. Health & Safety Code Ann.
§11362.77(a) (West Supp. 2005). However, the quantity limitations
serve only as a floor. Based on a doctor’s recommendation, a
patient can possess whatever quantity is necessary to satisfy his
medical needs, and cities and counties are given
carte
blanche to establish more generous limits. Indeed, several
cities and counties have done just that. For example, patients
residing in the cities of Oakland and Santa Cruz and in the
counties of Sonoma and Tehama are permitted to possess up to 3
pounds of processed marijuana. Reply Brief for United States 19
(citing Proposition 215 Enforcement Guidelines). Putting that
quantity in perspective, 3 pounds of marijuana yields roughly 3,000
joints or cigarettes. Executive Office of the President, Office of
National Drug Control Policy, What America’s Users Spend on Illegal
Drugs 24 (Dec. 2001),
http://www.whitehousedrugpolicy.gov/publications/pdf/american_users_spend_2002.pdf.
And the street price for that amount can range anywhere from $900
to $24,000. DEA, Illegal Drug Price and Purity Report (Apr. 2003)
(DEA–02058).
Footnote 42
For example, respondent Raich attests that
she uses 2.5 ounces of cannabis a week. App. 82. Yet as a resident
of Oakland, she is entitled to possess up to 3 pounds of processed
marijuana at any given time, nearly 20 times more than she uses on
a weekly basis.
Footnote 43
See,
e.g., People ex rel.
Lungren v.
Peron, 59 Cal. App. 4th 1383, 1386–1387
(1997) (recounting how a Cannabis Buyers’ Club engaged in an
“indiscriminate and uncontrolled pattern of sale to thousands of
persons among the general public, including persons who had not
demonstrated any recommendation or approval of a physician and, in
fact, some of whom were not under the care of a physician, such as
undercover officers,” and noting that “some persons who had
purchased marijuana on respondents’ premises were reselling it
unlawfully on the street”).
Comments
Be the first to comment
Leave a Comment